ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: Modulation of intracellular calcium homeostasis

Enrico Garattini, Edoardo Parrella, Luisa Diomede, Maurizio Gianni, Yesim Kalac, Lucio Merlini, Daniele Simoni, Romina Zanier, Fabiana Fosca Ferrara, Ilaria Chiarucci, Paolo Carminati, Mineko Terao, Claudio Pisano

Research output: Contribution to journalArticle

Abstract

Retinoid-related molecules (RRMs) are derivatives of retinoic acid and promising antileukemic agents with a mechanism of action different from that of other common chemotherapeutics. Here, we describe a novel chemical series designed against the RRM prototype, CD437. This includes molecules with apoptotic effects in acute promyelocytic leukemia and other myelogenous leukemia cell lines, as well as ST2065, an RRM with antagonistic properties. The most interesting apoptotic agent is ST1926, a compound more powerful than CD437 in vitro and orally active in vivo on severe combined immunodeficiency (SCID) mice that received transplants of NB4 cells. ST1926 has the same mechanism of action of CD437, as indicated by the ability to trans-activate retinoic acid receptor γ, to induce the phosphorylation of p38 and JNK, and to down-regulate the expression of many genes negatively modulated by CD437. ST1926 causes an immediate increase in the cytosolic levels of calcium that are directly related to the apoptotic potential of the RRMs considered. The intracellular calcium elevation is predominantly the result of an inhibition of the mitochondrial calcium uptake. The phenomenon is blocked by the ST2065 antagonist, the intracellular calcium chelator BAPTA (1,2 bis (2-aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid tetrakis (acetoxymethyl ester), and by high concentrations of calcium blockers of the dihydropyridine type, compounds that suppress ST1926-induced apoptosis.

Original languageEnglish
Pages (from-to)194-207
Number of pages14
JournalBlood
Volume103
Issue number1
DOIs
Publication statusPublished - Jan 1 2004

Fingerprint

Myeloid Leukemia
Retinoids
Myeloid Cells
Homeostasis
Modulation
Apoptosis
Calcium
Molecules
Tretinoin
Severe Combined Immunodeficiency
Acute Promyelocytic Leukemia
Retinoic Acid Receptors
Ethane
Transplants
Phosphorylation
Esters
Down-Regulation
Gene Expression
Cell Line
Genes

ASJC Scopus subject areas

  • Hematology

Cite this

ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells : Modulation of intracellular calcium homeostasis. / Garattini, Enrico; Parrella, Edoardo; Diomede, Luisa; Gianni, Maurizio; Kalac, Yesim; Merlini, Lucio; Simoni, Daniele; Zanier, Romina; Ferrara, Fabiana Fosca; Chiarucci, Ilaria; Carminati, Paolo; Terao, Mineko; Pisano, Claudio.

In: Blood, Vol. 103, No. 1, 01.01.2004, p. 194-207.

Research output: Contribution to journalArticle

Garattini, E, Parrella, E, Diomede, L, Gianni, M, Kalac, Y, Merlini, L, Simoni, D, Zanier, R, Ferrara, FF, Chiarucci, I, Carminati, P, Terao, M & Pisano, C 2004, 'ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: Modulation of intracellular calcium homeostasis', Blood, vol. 103, no. 1, pp. 194-207. https://doi.org/10.1182/blood-2003-05-1577
Garattini, Enrico ; Parrella, Edoardo ; Diomede, Luisa ; Gianni, Maurizio ; Kalac, Yesim ; Merlini, Lucio ; Simoni, Daniele ; Zanier, Romina ; Ferrara, Fabiana Fosca ; Chiarucci, Ilaria ; Carminati, Paolo ; Terao, Mineko ; Pisano, Claudio. / ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells : Modulation of intracellular calcium homeostasis. In: Blood. 2004 ; Vol. 103, No. 1. pp. 194-207.
@article{695d33c864a74109911c967acb637512,
title = "ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: Modulation of intracellular calcium homeostasis",
abstract = "Retinoid-related molecules (RRMs) are derivatives of retinoic acid and promising antileukemic agents with a mechanism of action different from that of other common chemotherapeutics. Here, we describe a novel chemical series designed against the RRM prototype, CD437. This includes molecules with apoptotic effects in acute promyelocytic leukemia and other myelogenous leukemia cell lines, as well as ST2065, an RRM with antagonistic properties. The most interesting apoptotic agent is ST1926, a compound more powerful than CD437 in vitro and orally active in vivo on severe combined immunodeficiency (SCID) mice that received transplants of NB4 cells. ST1926 has the same mechanism of action of CD437, as indicated by the ability to trans-activate retinoic acid receptor γ, to induce the phosphorylation of p38 and JNK, and to down-regulate the expression of many genes negatively modulated by CD437. ST1926 causes an immediate increase in the cytosolic levels of calcium that are directly related to the apoptotic potential of the RRMs considered. The intracellular calcium elevation is predominantly the result of an inhibition of the mitochondrial calcium uptake. The phenomenon is blocked by the ST2065 antagonist, the intracellular calcium chelator BAPTA (1,2 bis (2-aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid tetrakis (acetoxymethyl ester), and by high concentrations of calcium blockers of the dihydropyridine type, compounds that suppress ST1926-induced apoptosis.",
author = "Enrico Garattini and Edoardo Parrella and Luisa Diomede and Maurizio Gianni and Yesim Kalac and Lucio Merlini and Daniele Simoni and Romina Zanier and Ferrara, {Fabiana Fosca} and Ilaria Chiarucci and Paolo Carminati and Mineko Terao and Claudio Pisano",
year = "2004",
month = "1",
day = "1",
doi = "10.1182/blood-2003-05-1577",
language = "English",
volume = "103",
pages = "194--207",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells

T2 - Modulation of intracellular calcium homeostasis

AU - Garattini, Enrico

AU - Parrella, Edoardo

AU - Diomede, Luisa

AU - Gianni, Maurizio

AU - Kalac, Yesim

AU - Merlini, Lucio

AU - Simoni, Daniele

AU - Zanier, Romina

AU - Ferrara, Fabiana Fosca

AU - Chiarucci, Ilaria

AU - Carminati, Paolo

AU - Terao, Mineko

AU - Pisano, Claudio

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Retinoid-related molecules (RRMs) are derivatives of retinoic acid and promising antileukemic agents with a mechanism of action different from that of other common chemotherapeutics. Here, we describe a novel chemical series designed against the RRM prototype, CD437. This includes molecules with apoptotic effects in acute promyelocytic leukemia and other myelogenous leukemia cell lines, as well as ST2065, an RRM with antagonistic properties. The most interesting apoptotic agent is ST1926, a compound more powerful than CD437 in vitro and orally active in vivo on severe combined immunodeficiency (SCID) mice that received transplants of NB4 cells. ST1926 has the same mechanism of action of CD437, as indicated by the ability to trans-activate retinoic acid receptor γ, to induce the phosphorylation of p38 and JNK, and to down-regulate the expression of many genes negatively modulated by CD437. ST1926 causes an immediate increase in the cytosolic levels of calcium that are directly related to the apoptotic potential of the RRMs considered. The intracellular calcium elevation is predominantly the result of an inhibition of the mitochondrial calcium uptake. The phenomenon is blocked by the ST2065 antagonist, the intracellular calcium chelator BAPTA (1,2 bis (2-aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid tetrakis (acetoxymethyl ester), and by high concentrations of calcium blockers of the dihydropyridine type, compounds that suppress ST1926-induced apoptosis.

AB - Retinoid-related molecules (RRMs) are derivatives of retinoic acid and promising antileukemic agents with a mechanism of action different from that of other common chemotherapeutics. Here, we describe a novel chemical series designed against the RRM prototype, CD437. This includes molecules with apoptotic effects in acute promyelocytic leukemia and other myelogenous leukemia cell lines, as well as ST2065, an RRM with antagonistic properties. The most interesting apoptotic agent is ST1926, a compound more powerful than CD437 in vitro and orally active in vivo on severe combined immunodeficiency (SCID) mice that received transplants of NB4 cells. ST1926 has the same mechanism of action of CD437, as indicated by the ability to trans-activate retinoic acid receptor γ, to induce the phosphorylation of p38 and JNK, and to down-regulate the expression of many genes negatively modulated by CD437. ST1926 causes an immediate increase in the cytosolic levels of calcium that are directly related to the apoptotic potential of the RRMs considered. The intracellular calcium elevation is predominantly the result of an inhibition of the mitochondrial calcium uptake. The phenomenon is blocked by the ST2065 antagonist, the intracellular calcium chelator BAPTA (1,2 bis (2-aminophenoxy) ethane-N, N, N′, N′-tetraacetic acid tetrakis (acetoxymethyl ester), and by high concentrations of calcium blockers of the dihydropyridine type, compounds that suppress ST1926-induced apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=9144222122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144222122&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-05-1577

DO - 10.1182/blood-2003-05-1577

M3 - Article

C2 - 12958071

AN - SCOPUS:9144222122

VL - 103

SP - 194

EP - 207

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -